Cardiovascular Risk Reduction for Hypertriglyceridemia with Refined EPA (icosapent ethyl)
REDUCE-IT was a clinical trial funded by pharma to assess the safety and benefit of a highly concentrated form of the Omega-3 EPA, icosapent ethyl, in reducing cardiovascular events among patients with high triglycerides.
The refined Omega-3 EPA was subsequently approved by the FDA and given the brand name VASCEPA.
REDUCE-IT Reduction in total CV events were recently announced and included the following:
In statin-treated adults with well-controlled LDL-C and CV risk factors including TG > 135 mg/dL and either established CVD or diabetes and other CV risk factors the following was reported
- JAMA - Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- Vascepa (icosapent ethyl) Product Page - https://www.vascepahcp.com/